Investigational Drug Information for Esreboxetine
What is the development status for investigational drug Esreboxetine?
Esreboxetine is an investigational drug.
There have been 5 clinical trials for Esreboxetine.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 29th 2026.
The most common disease conditions in clinical trials are Fibromyalgia, Myofascial Pain Syndromes, and Hyperalgesia. The leading clinical trial sponsors are Pfizer, Axsome Therapeutics, Inc., and [disabled in preview].
Summary for Esreboxetine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,325 |
| WIPO Patent Applications | 2,340 |
| Japanese Patent Applications | 161 |
| Clinical Trial Progress | Phase 2 (2026-04-29) |
| Vendors | 20 |
Recent Clinical Trials for Esreboxetine
| Title | Sponsor | Phase |
|---|---|---|
| Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Axsome Therapeutics, Inc. | PHASE3 |
| Maintenance of Efficacy. | Pfizer | Phase 3 |
| Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine | Pfizer | Phase 1 |
Clinical Trial Summary for Esreboxetine
Top disease conditions for Esreboxetine
Top clinical trial sponsors for Esreboxetine
US Patents for Esreboxetine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Esreboxetine Development Update and Market Projection
Esreboxetine is an investigational selective norepinephrine reuptake inhibitor derived from reboxetine. Pfizer evaluated it primarily for fibromyalgia, neuropathic pain and related pain disorders. The program did not produce an approved medicine, and no active commercial development, FDA approval, Orange Book listing or established market exists. The base-case commercial forecast is therefore zero unless a sponsor restarts development with a new clinical strategy.
What is the current development status of esreboxetine?
Esreboxetine appears to be clinically inactive as a development program. Pfizer-sponsored studies evaluated the compound in fibromyalgia and painful diabetic neuropathy, but the program did not advance to FDA approval.
| Attribute | Status |
|---|---|
| Active ingredient | Esreboxetine, the pharmacologically active S-enantiomer associated with reboxetine |
| Mechanism | Selective norepinephrine reuptake inhibition |
| Original developer | Pfizer |
| Primary development areas | Fibromyalgia, painful diabetic neuropathy and other chronic pain indications |
| FDA approval | None |
| FDA regulatory designation | No publicly documented approved indication |
| Orange Book listing | None |
| Commercial product | None |
| Generic or biosimilar competition | None |
| Current market | No commercial market |
| Development outlook | Low without acquisition, reformulation or a new indication |
Clinical studies generated evidence of analgesic activity in some patient populations, but the total development package did not establish a commercially viable benefit-risk profile. The lack of an approved product and the absence of later-stage commercial activity indicate that esreboxetine is a discontinued or dormant asset rather than a near-term launch candidate.
What clinical trials were conducted for esreboxetine?
Esreboxetine was tested as a non-opioid treatment for chronic pain. The most visible development work focused on fibromyalgia and painful diabetic neuropathy.
Fibromyalgia studies
A randomized, placebo-controlled trial evaluated esreboxetine in patients with fibromyalgia. The study reported improvement in pain-related outcomes and some functional measures, but the clinical evidence was not sufficient to support regulatory approval or a broad commercial program (Schoenfeld et al., 2011).
Fibromyalgia is a difficult development setting because placebo response is high, patient-reported endpoints are variable, and regulators generally require durable improvement in pain and function. Esreboxetine also competed against established mechanisms, including serotonin-norepinephrine reuptake inhibitors and alpha-2-delta ligands.
Painful diabetic neuropathy studies
Esreboxetine was also investigated in painful diabetic neuropathy. The trial program did not establish a clear efficacy profile that could compete with approved or widely used treatments such as duloxetine and pregabalin.
The diabetic neuropathy setting requires consistent improvement in pain intensity, tolerability over extended treatment periods and a clinically acceptable cardiovascular and psychiatric safety profile. A selective norepinephrine mechanism can create exposure-response and tolerability concerns, particularly for blood pressure, heart rate, insomnia, anxiety and urinary symptoms.
Development conclusion
The available clinical record supports three conclusions:
- Esreboxetine had a plausible pharmacologic rationale for neuropathic and centralized pain.
- Clinical efficacy was inconsistent across indications and endpoints.
- The program did not transition into a successful regulatory filing or commercial launch.
What is the FDA and Orange Book status of esreboxetine?
Esreboxetine has no FDA-approved drug product and no Orange Book listing. The FDA Orange Book lists approved drug products, their active ingredients, dosage forms, marketing status and, where applicable, patents and regulatory exclusivity. Because esreboxetine was never approved, it has no FDA reference listed drug status and no standard abbreviated new drug application pathway tied to an approved esreboxetine product (U.S. Food and Drug Administration, n.d.-a).
| FDA-related item | Esreboxetine status |
|---|---|
| New Drug Application approval | None identified |
| Reference listed drug | None |
| Orange Book patent listing | None |
| Regulatory exclusivity | None currently applicable |
| Paragraph IV challenges | None applicable to an approved esreboxetine product |
| ANDA generic launch pathway | Not established |
| FDA-approved formulation | None |
A future sponsor would likely need to pursue a full 505(b)(1) or potentially a 505(b)(2) strategy, depending on the proposed product, supporting data and reliance on prior reboxetine information. A 505(b)(2) pathway could be relevant for a new dosage form or delivery system, but it would not eliminate the need to address esreboxetine-specific efficacy, safety, pharmacokinetics and clinical positioning.
What patents protect esreboxetine?
No active Orange Book patent estate protects esreboxetine because no esreboxetine product has been approved. Historical composition, stereochemical, formulation or method-of-use patents may have been filed around reboxetine or its enantiomers, but their commercial value depends on claim scope, jurisdiction, expiration, terminal disclaimers and enforceability.
The patent position is materially weaker than that of an approved product with listed formulation or method-of-use patents. A sponsor assessing the asset would need to distinguish among:
- Reboxetine composition patents.
- Esreboxetine stereoisomer or salt claims.
- Pharmaceutical composition claims.
- Chronic pain method-of-use claims.
- Combination-treatment claims.
- Process and crystallization claims.
- Delivery-system and extended-release claims.
Patent expiry is not equivalent to regulatory approval. Even if historical patents have expired, a new sponsor could seek protection for a novel formulation, dosing regimen or combination. Those claims would face validity and obviousness risks because esreboxetine and reboxetine have been publicly studied.
When does esreboxetine lose exclusivity?
Esreboxetine has no active FDA exclusivity period because it has no approved product. There is no Hatch-Waxman approval date from which five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity or pediatric exclusivity could run.
Historical patent protection may have existed, but it does not create current market exclusivity in the absence of an approved product. Any restart would require a new regulatory and intellectual-property strategy. A newly approved formulation could receive limited regulatory protection tied to the specific product and clinical data, but it would not automatically restore broad exclusivity for the active ingredient.
Which companies are challenging esreboxetine?
No company is publicly known to be challenging esreboxetine through a Paragraph IV filing, inter partes review, Abbreviated New Drug Application litigation or biosimilar litigation.
The reason is structural: Paragraph IV litigation generally requires an approved reference product with Orange Book-listed patents. Esreboxetine has neither. The competitive threat is therefore not an active generic challenge but the availability of existing generic and branded alternatives in the same therapeutic categories.
Relevant competitors
| Indication | Established alternatives |
|---|---|
| Fibromyalgia | Pregabalin, duloxetine and milnacipran |
| Painful diabetic neuropathy | Duloxetine, pregabalin, gabapentin, tricyclic antidepressants and topical therapies |
| Depression, if revisited | Generic reboxetine is not broadly marketed in the United States; multiple approved antidepressant classes compete |
| Chronic centralized pain | SNRIs, gabapentinoids, tricyclics and nonpharmacologic treatment |
Duloxetine and pregabalin are especially important benchmarks because both have extensive clinical use, established physician familiarity and generic availability.
What market could esreboxetine address?
The addressable market is substantial at the disease level but limited at the product level. Fibromyalgia affects millions of patients in the United States, while painful diabetic neuropathy affects a large subset of the growing diabetes population. The commercial opportunity would depend on differentiation rather than prevalence.
Potential positioning could include:
- A non-opioid treatment for neuropathic pain.
- A once-daily formulation with improved tolerability.
- A treatment for patients who do not respond to duloxetine or pregabalin.
- A product with less sedation or weight gain than some alternatives.
- A combination product for pain and mood symptoms.
Those advantages have not been demonstrated sufficiently in the public development record. A norepinephrine-focused mechanism could provide a differentiated pharmacologic profile, but it could also limit uptake if cardiovascular or activating adverse effects are prominent.
What is the market projection for esreboxetine?
The base-case forecast is no revenue because esreboxetine is not approved, marketed or in visible late-stage development.
Scenario-based commercial projection
| Scenario | Probability assessment | Commercial outcome |
|---|---|---|
| No restart | Highest-probability scenario | No revenue |
| Academic or specialty-indication restart | Low | Limited regional or niche sales if approved |
| Full chronic-pain redevelopment | Low | Potential specialty product, but high clinical and regulatory cost |
| Successful global launch | Very low | Material revenue only after new trials and regulatory approval |
A relaunch would require a costly clinical program. A plausible development sequence would include a modern dose-ranging study, a controlled proof-of-concept trial, confirmatory phase 3 studies, long-term safety follow-up and regulatory filings. The program would also need to establish why esreboxetine should be prescribed instead of generic duloxetine, pregabalin or other low-cost treatments.
A commercial forecast based solely on disease prevalence would overstate value. The relevant market is the treatment-experienced segment, particularly patients with inadequate response or intolerance to existing medicines. That segment is meaningful but difficult to capture because payers generally impose step-therapy requirements for chronic pain drugs.
How strong is the esreboxetine development and IP position?
The development position is weak for commercial purposes.
| Value driver | Assessment |
|---|---|
| Mechanistic rationale | Moderate |
| Clinical validation | Limited and inconsistent |
| Regulatory position | Weak; no approval |
| IP position | Unclear for historical claims, with no current Orange Book protection |
| Manufacturing complexity | Likely manageable for a small-molecule product |
| Differentiation | Unproven |
| Reimbursement position | Challenging against generic alternatives |
| Litigation exposure | Low today because no product is marketed |
| Restart cost | High relative to uncertain clinical value |
Manufacturing is unlikely to be the primary barrier. Esreboxetine is a small molecule, so production would generally be less complex than for a biologic. The more important barriers are clinical differentiation, patent durability, regulatory proof and payer adoption.
What manufacturing and formulation opportunities exist?
A new sponsor could investigate extended-release tablets, modified-release capsules, fixed-dose combinations or alternative delivery systems. Formulation patents could potentially create a new period of product protection if the formulation provides a genuine clinical or pharmacokinetic benefit.
The commercial rationale for formulation work would be strongest if it addresses:
- Peak-related adverse effects.
- Once-daily adherence.
- Stable exposure across the dosing interval.
- Reduced insomnia, anxiety or blood-pressure effects.
- Use in patients taking multiple chronic medications.
A formulation-only strategy would still face the need to prove that the new delivery system improves clinical utility. A reformulated product without measurable tolerability or adherence benefits would have limited pricing power.
How does esreboxetine compare with duloxetine and pregabalin?
| Factor | Esreboxetine | Duloxetine | Pregabalin |
|---|---|---|---|
| Regulatory status | Unapproved | Approved for several indications | Approved for several indications |
| Generic competition | No product market | Yes | Yes |
| Mechanism | Selective norepinephrine reuptake inhibitor | Serotonin-norepinephrine reuptake inhibitor | Alpha-2-delta ligand |
| Fibromyalgia positioning | Investigational only | Approved | Approved |
| Diabetic neuropathy positioning | Investigational only | Approved | Widely used; approved in relevant neuropathic pain settings |
| Physician familiarity | Low | High | High |
| Development risk | High | Low for existing use | Low for existing use |
| Pricing power | Unestablished | Limited by generics | Limited by generics |
Esreboxetine would need a clinically visible advantage to overcome the commercial strength of established generic therapies. A modest efficacy signal would likely be insufficient.
What generic launch risks exist for esreboxetine?
There is no immediate generic launch risk because no esreboxetine reference product exists. If the drug were approved, generic entry would depend on the approval pathway, listed patents and any surviving regulatory exclusivity.
The principal competitive risk would come from therapeutic substitution. Physicians and payers could use generic duloxetine, pregabalin or other treatments before adopting a new esreboxetine product. This substitution risk would affect pricing, formulary access and peak sales more than conventional Paragraph IV litigation.
Key Takeaways
- Esreboxetine is an unapproved Pfizer-derived norepinephrine reuptake inhibitor.
- Clinical development focused on fibromyalgia and painful diabetic neuropathy.
- The program did not produce an FDA filing, approval or commercial launch.
- Esreboxetine has no Orange Book listing, reference listed drug or active FDA exclusivity.
- No Paragraph IV challenge, biosimilar dispute or commercial patent litigation is associated with an approved esreboxetine product.
- The drug has no current market revenue.
- Any value would depend on a new sponsor demonstrating superior tolerability, adherence or efficacy against generic duloxetine, pregabalin and other established treatments.
- The base-case market projection is zero absent a development restart.
FAQs
Is esreboxetine the same drug as reboxetine?
No. Esreboxetine is the pharmacologically active enantiomer associated with reboxetine. Reboxetine is the racemic or marketed drug context, while esreboxetine was developed as a more selective stereoisomer.
Was esreboxetine approved for fibromyalgia?
No. Clinical studies evaluated esreboxetine in fibromyalgia, but the FDA did not approve it for that indication.
Can esreboxetine be prescribed in the United States?
There is no FDA-approved esreboxetine product available for routine U.S. prescribing.
Does esreboxetine have biosimilar risk?
No. Biosimilar rules apply to biological products. Esreboxetine is a small molecule, so any future competition would involve generic or therapeutically substitutable products rather than biosimilars.
Could esreboxetine still be revived?
Yes, technically, but revival would require a sponsor to fund new clinical and regulatory work. The commercial case would depend on proving an advantage over inexpensive generic therapies and securing defensible formulation, method-of-use or other intellectual-property protection.
References
-
ClinicalTrials.gov. (n.d.). Search results for esreboxetine clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Schoenfeld, M. J., et al. (2011). Randomized, placebo-controlled clinical evaluation of esreboxetine in fibromyalgia. Clinical Journal of Pain.
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Regulatory exclusivity and patent provisions for drug products. https://www.fda.gov/drugs/development-approval-process-drugs
-
Pfizer Inc. (n.d.). Clinical development and product information records. Pfizer corporate filings and clinical development disclosures. https://www.pfizer.com/
More… ↓
